ClinicalTrials.gg
RecruitingNCT07488104LEEF-shoeUpdated Mar 23, 2026

Plantar Pressure and Acceptance of the LEEF-shoe in Individuals With Diabetes-related Neuropathy

An interventional study of LEEF-shoe and standard orthopaedic shoe in Diabetic Neuropathy, sponsored by University Medical Center Groningen. Recruiting at 1 site in Netherlands. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-23.

Sponsored by University Medical Center Groningen · Not applicable, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 13 studies in Diabetic Neuropathies with a site in Netherlands — 1 open to participants now, 1 under way, none of them phase 3. Diabetic Neuropathies · Netherlands.

Planned enrollment
11th of 13
30 · median 40
Started
2026
the only one that year
No phase
6 of 13
1 open now
Registered
13th of 13
by date
Lead sponsor
1 of 13
University Medical Center Groningen

Among the 13 studies in Diabetic Neuropathies with a site in Netherlands, this one is the 11th largest by planned enrollment, is the only one that started in 2026, is one of 6 with no phase, and was the 13th registered.

Diabetic Neuropathies

539 studies on the registry are indexed under Diabetic Neuropathies; 80 are open to participants now.

Browse Diabetic Neuropathies studies →

Open to participants now

1 of the 13 studies in Diabetic Neuropathies with a site in Netherlands is open now.

A study can be open while its sites in Netherlands have not opened yet or have stopped. Only those recruiting at a site in Netherlands →

Who these studies take

Of the 52 Diabetic Neuropathies studies recruiting now, 21 (40%) set no upper age limit and 24 (46%) stop at 75 or younger; 6 take children under 18; 3 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Diabetic Neuropathies with a site in Netherlands, or all of them as a file.
02

Study summary

Rationale: Of all individuals with diabetes, 19-34% develop a foot ulcer in their lifetime, and nearly 25% of these ulcers result in amputation. Ulcer prevention is often addressed by prescribing orthopedic shoes (OS). However, the effectiveness of OS is highly dependent on the individual shoe technician's skill and experience, and OS is frequently perceived as unattractive by users.

To overcome these limitations, the LEEF-shoe was developed. It eliminates the need for a fully individualized shoe technician approach by using a standardized protocol to determine the rocker settings. This may provide comparable plantar pressure relief, while potentially improving patient acceptance due to its more appealing design and simplified prescription process.

Objective: The primary objective is to determine whether the LEEF-shoe differs from standard-OS in terms of plantar pressure distribution. Secondary objectives are evaluation of wearing time and user acceptance of both footwear types.

Study design: This study is a randomized cross-over trial. Participants will complete pre- and post-tests for plantar pressure distribution, wearing time will be measured, and focus group sessions will assess user experience and acceptance.

Study population: A total of 30 adults (≥18 years old) with diabetes mellitus and peripheral neuropathy, at increased risk for foot ulceration, will be included.

Intervention:

All participants will receive two pairs of OS, a standard-OS and an additional OS (e.g., the LEEF-shoe), both provided through usual care channels. At handover, plantar pressure measurements will be performed. Participants will then wear each shoe model for four weeks, one after the other, with wearing time continuously monitored. Following the 8-week period, participants return for a standard control appointment with the OS-technician, during which post-test pressure measurements are taken. Subsequently, participants are allowed to wear either shoe based on personal preference for an additional four weeks, during which wearing time continues to be recorded. The study concludes with focus group sessions to explore experiences and acceptance.

Main study parameters/endpoints:

The primary outcome of the study is peak plantar pressure. It will be compared between the standard-OS and LEEF-shoe during the randomization visit. The secondary outcomes are peak plantar pressures in 7 foot regions, wearing time of the OS and user experience and acceptance, assessed through semi-structured focus groups.

Nature and extent of the burden and risks associated with participation, benefit and group relatedness: Participants will be screened for eligibility during their regular consultation with the prescribing physician and OS-technician. After inclusion, participants will follow standard care procedures, which include an initial shoe fitting, a midway fitting, the handover of both shoes, and two follow-up appointments. To minimize any potential risk associated with wearing the LEEF-shoe at home following the handover, it is required that the LEEF-shoe is at least equivalent to, or better than, the standard-OS in terms of function and safety. Since the LEEF-shoe is produced within the existing framework and standards of OS manufacturing, it is considered a variant of standard-OS and thus falls within the boundaries of standard care.

03

Conditions studied

  • Diabetic Neuropathy

Keywords

  • orthopaedic footwear
  • Diabetes Mellitus
  • Diabetic foot
  • Wearing time
  • Plantar pressure
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 18 years or older
  • Diabetes mellitus type 1 or 2
  • IWGDF Risk 2 - 3
  • Prescribed with fully custom-made orthopedic footwear (OS type A)
  • Ability to provide

Exclusion criteria

Exclusion Criteria:

  • Severe foot deformities
  • Active Charcot's neuroarthropathy
  • Foot ulcer or open amputation site
  • Severe illness, based on clinical judgment by the physician
  • Not able to walk at least 10 meters uninterrupted
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    LEEF-shoe then standard orthopaedic shoe

    First four weeks wear of the LEEF-shoe, then four weeks wear of the standard orthopaedic shoe. Followed by four weeks of free shoe choice.

    Device: LEEF-shoe · Device: standard orthopaedic shoe

  • Experimental
    Standard orthopaedic shoe then LEEF-shoe

    First four weeks wear of the LEEF-shoe, then four weeks wear of the standard orthopaedic shoe. Followed by four weeks of free shoe choice.

    Device: LEEF-shoe · Device: standard orthopaedic shoe

Interventions

  • DeviceLEEF-shoe

    The LEEF-shoe is a variant of a standard-OS and therefore follows identical classification. The LEEF-shoe is classified as custom-made medical devices under EU Medical Device Regulation (MDR), as they are prescribed in writing, designed with specific characteristics, and intended for the exclusive use of an individual patient. Consequently, they are exempt from CE-marking requirements. The processes at STEPP BV for these custom-made medical devices are ISO 13485 certified. This certification is also required for the production of medical devices. These processes are governed by Standard Operating Procedures (SOP), which describe how the process is to be carried out. The LEEF-shoe utilizes a rocker algorithm (simple search) to optimize the shape. Both ways of producing OS (Standard-OS \& LEEF-shoe) fit in the SOPs of STEPP BV, following ISO 13485. Standard-OS shoes typically consist of a supplement onto which the outsole is attached. The upper encloses the supplement. The suppleme

  • Devicestandard orthopaedic shoe

    The standard orthopaedic shoe, which is the care as usual solution in the Netherland. ISO 13485 certified and optimized individually.

06

What researchers measure

Primary outcomes

  1. In-shoe peak plantar pressure

    Measured with the Pedar-X measurement system

    Time frame: measured during the handover of both shoes, before the wearing periods.

Secondary outcomes

  1. In-Shoe peak plantar pressure

    Measured with the Pedar-X measurement system

    Time frame: measured after the two wearing time periods (totalling 8 weeks)

  2. Wearing time

    wearing time (adherence) measured with a orthotimer in each shoe

    Time frame: collected during the three subsequent wearing periods of four weeks

  3. Shoe mass

    The weight of both pair of orthopedic shoes.

    Time frame: measured during the handover of both shoes, before the wearing periods

  4. Body mass

    The weight of the participant.

    Time frame: After enrollment, baseline

  5. Focus group

    Semi-structured interview regarding acceptance.

    Time frame: After completion of the total protocol, after 12 weaks of wearing the ortopedic shoes.

  6. Participant height

    Height of the participant.

    Time frame: After enrollment, baseline

  7. Participants foot length

    the length of the feet of the participants.

    Time frame: After enrollment, baseline

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Malki A, Baltasar Badaya M, Dekker R, Verkerke GJ, Hijmans JM. Effects of individually optimized rocker midsoles and self-adjusting insoles on plantar pressure in persons with diabetes mellitus and loss of protective sensation. Diabetes Res Clin Pract. 2024 Jan;207:111077. doi: 10.1016/j.diabres.2023.111077. Epub 2023 Dec 26. PubMed 38154536 ↗
  • Exterkate SH, Jongebloed-Westra M, Ten Klooster PM, Koffijberg H, Bode C, van Gemert-Pijnen JEWC, van Baal JG, van Netten JJ. Objectively assessed long-term wearing patterns and predictors of wearing orthopaedic footwear in people with diabetes at moderate-to-high risk of foot ulceration: a 12 months observational study. J Foot Ankle Res. 2023 Sep 14;16(1):60. doi: 10.1186/s13047-023-00656-6. PubMed 37705016 ↗
  • Armstrong DG, Boulton AJM, Bus SA. Diabetic Foot Ulcers and Their Recurrence. N Engl J Med. 2017 Jun 15;376(24):2367-2375. doi: 10.1056/NEJMra1615439. No abstract available. PubMed 28614678 ↗

Individual participant data

Plan to share: Yes — Data will be stored in a registry or be made available upon reasonable request.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Apr 2026; primary completion for Oct 2026, 6 months later.

Of 138 non-industry interventional studies with no phase under Diabetic Neuropathies, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 24. This study's planned 6 months is below that.

Counting every sponsor, half of 153 studies reached it within 11 months; a quarter within 6 and three quarters within 28.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 3, 2026
First posted
Mar 23, 2026
StartEst.
Apr 2026
Primary completionEst.
Oct 2026
CompletionEst.
Jan 1, 2027
Last update
Mar 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07488104
Collaborators
Amsterdam UMC
Responsible party
Sponsor
First posted
Mar 23, 2026
Start date
Apr 2026 (estimated)
Primary completion
Oct 2026 (estimated)
Completion
Jan 1, 2027 (estimated)
Last update
Mar 23, 2026

Study contacts

Jelmer Braaksma, PhD
Contact
j.braaksma01@umcg.nl
+31 6 24665798
Juha M Hijmans, PhD
Contact
j.m.hijmans@umcg.nl
+31 (0)6 55256225

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion